Volitionrx Limited (VNRX) Issues Business Review 2024
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street closes lower as oil prices jump, indexes notch monthly gains
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
Volition Issues Business Review 2024
January 8, 2025 8:30 AM ESTHENDERSON, Nev., Jan. 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, has issued a Business Review of 2024, outlining its key highlights from the past year.
Volition's major achievements in 2024 include:
Expanded access to the Nu.Q® Vet Cancer Test now available for purchase in 20 countries worldwide.Sold over 110,000 Nu.Q® Vet... More